IndiaDailyUpdate.com
Fast mobile article powered by Nexiamath-SEO AMP.
AMP Article

Psychedelic drug offers new route out of stubborn depression

Published October 31, 2026 · Updated October 31, 2026 · By Charles Moore - indiadailyupdate.com

Foto : Charles Moore - indiadailyupdate.com

A Fast-Acting Psychedelic Is Being Studied for Treatment-Resistant Depression

Indiadailyupdate.com – For people whose depression has not improved after standard medicines, the usual path can be long and discouraging. Antidepressants often require four to six weeks before a patient and clinician can judge whether they are working. When one medicine fails, the dose may be adjusted or another drug prescribed, beginning another waiting period.

Depression is generally described as treatment-resistant after two antidepressants, taken at adequate doses for an adequate duration, have not produced sufficient improvement. The European Medicines Agency uses the same two-treatment benchmark. Recovery tends to become less likely as additional medicines are tried. In STAR*D, the largest US study tracking patients through successive treatments, roughly 37% recovered after the first medicine and 31% after the second. By the third or fourth treatment, the figure was about 13%.

A 2021 US estimate suggested that about 31% of adults receiving antidepressants met the criteria for treatment-resistant depression. For this group, research into treatments that act more quickly is especially important.

Single-dose study shows sustained symptom reduction

A randomised controlled trial published in JAMA examined mebufotenin, a psychedelic compound, in 193 people with treatment-resistant depression. Participants received one spray of the drug, whose psychoactive effects generally fade within an hour. Most were ready to leave within two hours, and the group given mebufotenin maintained lower depression symptoms than the comparison group over the next eight weeks.

The trial attracts attention not only because of the result, but because it used a randomised controlled design. This type of study is designed to compare outcomes between groups while reducing the influence of chance and expectations. Psychedelic research presents a particular challenge, however: participants can often recognise whether they have received an active psychedelic rather than a placebo.

Mebufotenin’s short duration may be a practical advantage if it eventually proves safe and effective. Some psychedelic-assisted sessions can occupy much of a day, requiring monitoring before, during and after the experience. A treatment whose acute effects conclude within about an hour could potentially be easier to deliver in supervised clinical settings, though further evidence and regulatory assessment would be required.

Existing options can be effective but demanding

People with persistent depression already have several options, but each brings limitations. Electroconvulsive therapy, or ECT, involves inducing a brief seizure while the patient is under anaesthesia. Around half of treatment-resistant patients may enter remission with ECT, but treatment normally involves repeated sessions over several weeks. Some patients also experience memory-related effects.

Magnetic brain stimulation is another approach. It commonly requires appointments every weekday for four to six weeks, and approximately three in ten patients respond. Ketamine, an anaesthetic, may ease depressive symptoms within hours, although the benefit can fade. Following these treatments, many people relapse unless they continue taking an antidepressant.

That background helps explain why a faster intervention is generating interest. Yet the new findings do not establish mebufotenin as a complete solution for treatment-resistant depression.

“The antidepressant effect was incomplete.”

Chittaranjan Andrade, a psychopharmacologist at Nimhans in Bengaluru, made that observation in an editorial published alongside the trial. On average, participants improved by about 30%. None had previously tried ketamine or ECT, and people with suicidal thoughts were excluded. In addition, many participants may have been able to identify whether they had received the active dose. The company developing mebufotenin funded the study.

“If the benefit is only 30%, it means that you’ve either not given an adequate dose, or you’ve not given it on an adequate number of occasions.”

Those limitations matter when interpreting early results. A reduction in symptoms can be meaningful, particularly for people who have struggled through several unsuccessful treatments. But symptom improvement is different from full remission, and the trial does not answer every question about dose, repeat treatment, long-term safety or how the drug would perform in broader groups of patients.

Psychedelic research faces scientific and regulatory hurdles

Psychedelics have been investigated for mental-health conditions for years, yet none has been approved by a regulator for depression. Concerns extend beyond effectiveness to study quality, safety, supervision and the difficulty of maintaining blinding.

In 2024, the US Food and Drug Administration rejected MDMA for post-traumatic stress disorder, citing several issues, including the possibility that participants knew which treatment they had received. Psilocybin, the compound associated with psychedelic mushrooms, has since cleared two large trials by a modest margin. Its treatment sessions can last for hours, one reason researchers have explored a shorter-acting compound such as mebufotenin.

Outside clinical research, mebufotenin may be smoked at retreats in the form of dried toad secretion. That use is very different from a medical study, where participants are screened and monitored. The absence of screening or clinical oversight can add risks, especially for people with serious mental-health symptoms or other health conditions.

What the findings mean for India

No Indian participants were involved in the mebufotenin trials. Psilocybin and DMT are prohibited under India’s Narcotic Drugs and Psychotropic Substances Act, and Andrade expects psychedelic treatments to remain “unavailable and unaffordable” in the country even if they receive approval in the United States.

He has instead highlighted ketamine, which Indian clinicians can prescribe off-label. Oral ketamine, he notes, requires limited training and involves negligible cost, though its broader use still needs stronger research support. Andrade has led substantial Indian research into oral ketamine.

The central lesson is not that people should seek psychedelics outside medical care. It is that treatment-resistant depression remains an urgent area for better therapies: ones that work more quickly, are practical to deliver and can sustain benefit safely. Mebufotenin has offered an encouraging signal, but larger and more rigorous research will determine whether that promise can become a reliable treatment option.

Related Reading

Frequently Asked Questions

What is Psychedelic drug offers new route out?

Psychedelic drug offers new route out is the main topic of this guide. The article explains the context, practical details, and next steps readers should understand.

Why does Psychedelic drug offers new route out matter?

Psychedelic drug offers new route out matters because readers are looking for a useful answer, not just a short summary. Good content should match search intent and help them decide what to do next.